Celldex (CLDX) –
-
Form ARS Celldex Therapeutics, For: Dec 31
-
Form DEF 14A Celldex Therapeutics, For: Jun 13
-
Celldex (CLDX) Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
-
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
-
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
-
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
-
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Form 8-K Celldex Therapeutics, For: Feb 28
-
Form 424B5 Celldex Therapeutics,
-
Celldex (CLDX) Announces Pricing of $400 mln Public Offering of Common Stock
-
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
-
Form 424B5 Celldex Therapeutics,
-
Celldex (CLDX) Announces Proposed $250M Share Offering
-
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
-
Celldex Therapeutics (CLDX) PT Raised to $35 at Wells Fargo
-
Celldex Therapeutics (CLDX) PT Raised to $90 at Guggenheim
-
Form 424B5 Celldex Therapeutics,
-
Celldex (CLDX) Misses Q4 EPS by 7c
-
Form 10-K Celldex Therapeutics, For: Dec 31
-
Form 8-K Celldex Therapeutics, For: Feb 26
-
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
-
Celldex (CLDX) Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study
-
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
-
Celldex (CLDX) March calls active
-
Celldex (CLDX) March call spreader active
-
Form 4 Celldex Therapeutics, For: Feb 13 Filed by: Jimenez Freddy A.
-
Form SC 13G/A Celldex Therapeutics, Filed by: Point72 Asset Management, L.P.
-
Form SC 13G Celldex Therapeutics, Filed by: Kynam Capital Management, LP
-
Form SC 13G Celldex Therapeutics, Filed by: EVENTIDE ASSET MANAGEMENT, LLC
-
Form SC 13G/A Celldex Therapeutics, Filed by: RTW INVESTMENTS, LP
-
Form SC 13G/A Celldex Therapeutics, Filed by: VANGUARD GROUP INC
-
Form SC 13G Celldex Therapeutics, Filed by: Polar Capital Holdings Plc
-
Form SC 13G/A Celldex Therapeutics, Filed by: FMR LLC
-
Form SC 13G/A Celldex Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
-
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
-
Form SC 13G/A Celldex Therapeutics, Filed by: BlackRock Inc.
-
Form 4 Celldex Therapeutics, For: Jan 02 Filed by: Martin Samuel Bates
-
TD Cowen Starts Celldex Therapeutics (CLDX) at Outperform; 'barzolvolimab has blockbuster potential'
-
Celldex (CLDX) call put ratio 1 call to 13 puts with focus on January puts
-
Celldex (CLDX) call put ratio 1 call to 21 puts with focus on January puts
-
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
-
Steven Cohen's Point72 Reports 6.6% Passive Stake in Celldex (CLDX)
-
Form SC 13G Celldex Therapeutics, Filed by: Point72 Asset Management, L.P.
-
Wells Fargo Upgrades Celldex Therapeutics (CLDX) to Equal Weight
-
Form 8-K Celldex Therapeutics, For: Nov 07
-
Form 424B5 Celldex Therapeutics,
-
Celldex (CLDX) Prices 7.43M Share Offering at $27/sh
-
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
-
Celldex (CLDX) Announces Proposed Share Offering, Size not Disclosed
Back to CLDX Stock Lookup